Pfizer makes new case for controversial Mylotarg

Pfizer ($PFE) has potentially found a second life for its controversial blood cancer drug Mylotarg, Bloomberg reports. From 2000 to 2010, the drug was used to treat patients with acute myeloid leukemia--aged 60 or older--after their cancer had returned. But the FDA asked Pfizer to stop selling it last year after a post-marketing trial showed the drug wasn't helping patients and some died from related liver complications. A new study showed that Mylotarg, along with chemotherapy, helped prolong the lives of patients who were just diagnosed with the deadly cancer, compared with chemotherapy alone. Story

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.